Pediatric Diffuse Hemispheric Glioma H3 G34-mutant with Gains of the BRAF Locus: An Illustrative Case

Overview

Journal Rare Tumors

Publisher Sage Publications

Specialty Oncology

Date 2023 Apr 14

PMID 37056711

Authors

Christine Marlow

Joshua A Cuoco

Austin R Hoggarth

Michael S Stump

Lisa S Apfel

Cara M Rogers

Affiliations

Soon will be listed here.

Abstract

Diffuse hemispheric glioma, H3 G34-mutant, is a recently recognized distinct high-grade glioma with a dismal prognosis. In addition to the H3 G34 missense mutation, numerous genetic events have been identified in these malignant tumors, including , , and, rarely, genes. There are only a few reports to date that have identified mutations in diffuse hemispheric glioma, H3 G34-mutant. Moreover, to our knowledge, gains of the locus have yet to be described. Here, we present a case of an 11-year-old male with a diffuse hemispheric glioma, H3 G34-mutant, found to have novel gains of the locus. Furthermore, we emphasize the current genetic landscape of diffuse hemispheric glioma, H3 G34-mutant, and implications of an aberrant BRAF signaling pathway.

Citing Articles

A scoping review of diffuse hemispheric glioma, H3 G34-mutant: Epigenetic and molecular profiles, clinicopathology, and treatment avenues.

Tang K, Cesaire M, McDonald T, Cimino P, Castro M, Jackson S Neurooncol Adv. 2025; 6(1):vdae208.

PMID: 39759262 PMC: 11697104. DOI: 10.1093/noajnl/vdae208.

Myeloid cells as potential targets for immunotherapy in pediatric gliomas.

Frederico S, Sharma N, Darling C, Taori S, Dubinsky A, Zhang X Front Pediatr. 2024; 12:1346493.

PMID: 38523840 PMC: 10960498. DOI: 10.3389/fped.2024.1346493.

Review on neuroimaging in pediatric-type diffuse low-grade gliomas.

Chen J, Qi X, Zhang M, Zhang J, Han T, Wang C Front Pediatr. 2023; 11:1149646.

PMID: 37920791 PMC: 10619148. DOI: 10.3389/fped.2023.1149646.

References

Robinson J, VanBrocklin M, Guilbeault A, Signorelli D, Brandner S, Holmen S . Activated BRAF induces gliomas in mice when combined with Ink4a/Arf loss or Akt activation. Oncogene. 2009; 29(3):335-44. PMC: 4109991. DOI: 10.1038/onc.2009.333. View

Puntonet J, Dangouloff-Ros V, Saffroy R, Pages M, Andreiuolo F, Grill J . Historadiological correlations in high-grade glioma with the histone 3.3 G34R mutation. J Neuroradiol. 2018; 45(5):316-322. DOI: 10.1016/j.neurad.2018.02.006. View

Lyustikman Y, Momota H, Pao W, Holland E . Constitutive activation of Raf-1 induces glioma formation in mice. Neoplasia. 2008; 10(5):501-10. PMC: 2373912. DOI: 10.1593/neo.08206. View

Raabe E, Lim K, Kim J, Meeker A, Mao X, Nikkhah G . BRAF activation induces transformation and then senescence in human neural stem cells: a pilocytic astrocytoma model. Clin Cancer Res. 2011; 17(11):3590-9. PMC: 4086658. DOI: 10.1158/1078-0432.CCR-10-3349. View

Behling F, Schittenhelm J . Oncogenic BRAF Alterations and Their Role in Brain Tumors. Cancers (Basel). 2019; 11(6). PMC: 6627484. DOI: 10.3390/cancers11060794. View

Onishi S, Amatya V, Karlowee V, Takeshima Y, Sugiyama K, Kurisu K . Radiological and Immunostaining Characteristics of H3.3 G34R-Mutant Glioma: A Report of 3 Cases and Review of the Literature. Pediatr Neurosurg. 2020; 55(5):319-325. DOI: 10.1159/000511672. View

Wood M, Neff T, Nickerson J, Sayama C, Raslan A, Ambady P . Post-treatment hypermutation in a recurrent diffuse glioma with H3.3 p.G34 Mutation. Neuropathol Appl Neurobiol. 2020; 47(3):460-463. DOI: 10.1111/nan.12679. View

Jeuken J, Van den Broecke C, Gijsen S, Boots-Sprenger S, Wesseling P . RAS/RAF pathway activation in gliomas: the result of copy number gains rather than activating mutations. Acta Neuropathol. 2007; 114(2):121-33. DOI: 10.1007/s00401-007-0239-0. View

Stagni C, Zamuner C, Elefanti L, Zanin T, Del Bianco P, Sommariva A . Gene Copy Number and Mutant Allele Frequency Correlate with Time to Progression in Metastatic Melanoma Patients Treated with MAPK Inhibitors. Mol Cancer Ther. 2018; 17(6):1332-1340. DOI: 10.1158/1535-7163.MCT-17-1124. View

10.

Srinivasa K, Cross K, Dahiya S . Alteration in Central and Peripheral Nervous System Tumors. Front Oncol. 2020; 10:574974. PMC: 7523461. DOI: 10.3389/fonc.2020.574974. View

11.

Lim K, Won J, Park C, Kim S, Choi S, Kim T . H3 G34-mutant high-grade glioma. Brain Tumor Pathol. 2020; 38(1):4-13. DOI: 10.1007/s10014-020-00378-8. View

12.

Kim Y, Nonoguchi N, Paulus W, Brokinkel B, Keyvani K, Sure U . Frequent BRAF gain in low-grade diffuse gliomas with 1p/19q loss. Brain Pathol. 2012; 22(6):834-40. PMC: 8057626. DOI: 10.1111/j.1750-3639.2012.00601.x. View

13.

Vuong H, Le H, Dunn I . The prognostic significance of further genotyping H3G34 diffuse hemispheric gliomas. Cancer. 2022; 128(10):1907-1912. DOI: 10.1002/cncr.34156. View

14.

Ahn J, Lee Y, Ahn S, Lee M . Oncogenic BRAF inhibitor UAI-201 induces cell cycle arrest and autophagy in BRAF mutant glioma cells. Life Sci. 2014; 104(1-2):38-46. DOI: 10.1016/j.lfs.2014.03.026. View

15.

Yoshimoto K, Hatae R, Sangatsuda Y, Suzuki S, Hata N, Akagi Y . Prevalence and clinicopathological features of H3.3 G34-mutant high-grade gliomas: a retrospective study of 411 consecutive glioma cases in a single institution. Brain Tumor Pathol. 2017; 34(3):103-112. DOI: 10.1007/s10014-017-0287-7. View

16.

Cantwell-Dorris E, OLeary J, Sheils O . BRAFV600E: implications for carcinogenesis and molecular therapy. Mol Cancer Ther. 2011; 10(3):385-94. DOI: 10.1158/1535-7163.MCT-10-0799. View

17.

Picart T, Barritault M, Poncet D, Berner L, Izquierdo C, Tabouret E . Characteristics of diffuse hemispheric gliomas, H3 G34-mutant in adults. Neurooncol Adv. 2021; 3(1):vdab061. PMC: 8156974. DOI: 10.1093/noajnl/vdab061. View

18.

Kurokawa R, Baba A, Kurokawa M, Pinarbasi E, Makise N, Ota Y . Neuroimaging features of diffuse hemispheric glioma, H3 G34-mutant: A case series and systematic review. J Neuroimaging. 2021; 32(1):17-27. DOI: 10.1111/jon.12939. View

19.

Khuong-Quang D, Buczkowicz P, Rakopoulos P, Liu X, Fontebasso A, Bouffet E . K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. Acta Neuropathol. 2012; 124(3):439-47. PMC: 3422615. DOI: 10.1007/s00401-012-0998-0. View

20.

Louis D, Perry A, Wesseling P, Brat D, Cree I, Figarella-Branger D . The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021; 23(8):1231-1251. PMC: 8328013. DOI: 10.1093/neuonc/noab106. View